Literature DB >> 25451059

Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro.

Giuseppe Belardo1, Orlando Cenciarelli1, Simone La Frazia1, Jean Francois Rossignol2, M Gabriella Santoro3.   

Abstract

The emergence of drug-resistant influenza A virus (IAV) strains represents a serious threat to global human health and underscores the need for novel approaches to anti-influenza chemotherapy. Combination therapy with drugs affecting different IAV targets represents an attractive option for influenza treatment. We have previously shown that the thiazolide anti-infective nitazoxanide (NTZ) inhibits H1N1 IAV replication by selectively blocking viral hemagglutinin maturation. Herein we investigate the anti-influenza activity of NTZ against a wide range of human and avian IAVs (H1N1, H3N2, H5N9, H7N1), including amantadine-resistant and oseltamivir-resistant strains, in vitro. We also investigate whether therapy with NTZ in combination with the neuraminidase inhibitors oseltamivir and zanamivir exerts synergistic, additive, or antagonistic antiviral effects against influenza viruses. NTZ was effective against all IAVs tested, with 50% inhibitory concentrations (IC50s) ranging from 0.9 to 3.2 μM, and selectivity indexes (SIs) ranging from >50 to >160, depending on the strain and the multiplicity of infection (MOI). Combination therapy studies were performed in cell culture-based assays using A/Puerto Rico/8/1934 (H1N1), A/WSN/1933 (H1N1), or avian A/chicken/Italy/9097/1997 (H5N9) IAVs; dose-effect analysis and synergism/antagonism quantification were performed using isobologram analysis according to the Chou-Talalay method. Combination index (CI) analysis indicated that NTZ and oseltamivir combination treatment was synergistic against A/Puerto Rico/8/1934 (H1N1) and A/WSN/1933 (H1N1) IAVs, with CI values ranging between 0.39 and 0.63, independently of the MOI used. Similar results were obtained when NTZ was administered in combination with zanamivir (CI=0.3 to 0.48). NTZ-oseltamivir combination treatment was synergistic also against the avian A/chicken/Italy/9097/1997 (H5N9) IAV (CI=0.18 to 0.31). Taken together, the results suggest that regimens that combine neuraminidase inhibitors and nitazoxanide exert synergistic anti-influenza effects.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25451059      PMCID: PMC4335909          DOI: 10.1128/AAC.03947-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Influenza: options to improve pandemic preparation.

Authors:  Rino Rappuoli; Philip R Dormitzer
Journal:  Science       Date:  2012-06-22       Impact factor: 47.728

2.  Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Eur J Biochem       Date:  1981-03-16

Review 3.  Drugs in development for influenza.

Authors:  David A Boltz; Jerry R Aldridge; Robert G Webster; Elena A Govorkova
Journal:  Drugs       Date:  2010-07-30       Impact factor: 9.546

4.  The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation.

Authors:  Menashe Elazar; Michael Liu; Sean A McKenna; Ping Liu; Elizabeth A Gehrig; Joseph D Puglisi; Jean-François Rossignol; Jeffrey S Glenn
Journal:  Gastroenterology       Date:  2009-08-04       Impact factor: 22.682

5.  Delta(12)-prostaglandin J(2) is a potent inhibitor of influenza A virus replication.

Authors:  F Pica; A T Palamara; A Rossi; A De Marco; C Amici; M G Santoro
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

6.  Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.

Authors:  Jean-François Rossignol; Asem Elfert; Yehia El-Gohary; Emmet B Keeffe
Journal:  Gastroenterology       Date:  2008-11-19       Impact factor: 22.682

7.  Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance.

Authors:  Yunwen Hu; Shuihua Lu; Zhigang Song; Wei Wang; Pei Hao; Jianhua Li; Xiaonan Zhang; Hui-Ling Yen; Bisheng Shi; Tao Li; Wencai Guan; Lei Xu; Yi Liu; Sen Wang; Xiaoling Zhang; Di Tian; Zhaoqin Zhu; Jing He; Kai Huang; Huijie Chen; Lulu Zheng; Xuan Li; Jie Ping; Bin Kang; Xiuhong Xi; Lijun Zha; Yixue Li; Zhiyong Zhang; Malik Peiris; Zhenghong Yuan
Journal:  Lancet       Date:  2013-05-29       Impact factor: 79.321

8.  Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards.

Authors:  Josef D Järhult; Shaman Muradrasoli; John Wahlgren; Hanna Söderström; Goran Orozovic; Gunnar Gunnarsson; Caroline Bröjer; Neus Latorre-Margalef; Jerker Fick; Roman Grabic; Johan Lennerstrand; Jonas Waldenström; Ake Lundkvist; Björn Olsen
Journal:  PLoS One       Date:  2011-09-12       Impact factor: 3.240

Review 9.  Avian influenza A (H5N1).

Authors:  Menno D de Jong; Tran Tinh Hien
Journal:  J Clin Virol       Date:  2005-10-06       Impact factor: 3.168

10.  New world bats harbor diverse influenza A viruses.

Authors:  Suxiang Tong; Xueyong Zhu; Yan Li; Mang Shi; Jing Zhang; Melissa Bourgeois; Hua Yang; Xianfeng Chen; Sergio Recuenco; Jorge Gomez; Li-Mei Chen; Adam Johnson; Ying Tao; Cyrille Dreyfus; Wenli Yu; Ryan McBride; Paul J Carney; Amy T Gilbert; Jessie Chang; Zhu Guo; Charles T Davis; James C Paulson; James Stevens; Charles E Rupprecht; Edward C Holmes; Ian A Wilson; Ruben O Donis
Journal:  PLoS Pathog       Date:  2013-10-10       Impact factor: 6.823

View more
  29 in total

1.  Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations.

Authors:  April C Joice; Sihyung Yang; Abdelbasset A Farahat; Heidi Meeds; Mei Feng; Junan Li; David W Boykin; Michael Zhuo Wang; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 2.  Respiratory Infections in the U.S. Military: Recent Experience and Control.

Authors:  Jose L Sanchez; Michael J Cooper; Christopher A Myers; James F Cummings; Kelly G Vest; Kevin L Russell; Joyce L Sanchez; Michelle J Hiser; Charlotte A Gaydos
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

3.  Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses.

Authors:  Tianguang Huang; Lin Sun; Dongwei Kang; Vasanthanathan Poongavanam; Xinyong Liu; Peng Zhan; Luis Menéndez-Arias
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Emergent Pneumonia in Children.

Authors:  Cecilia Perret; Nicole Le Corre; Jose A Castro-Rodriguez
Journal:  Front Pediatr       Date:  2021-06-17       Impact factor: 3.418

5.  Synergistic Effects of Sulfated Polysaccharides from Mexican Seaweeds against Measles Virus.

Authors:  Karla Morán-Santibañez; Lucia Elizabeth Cruz-Suárez; Denis Ricque-Marie; Daniel Robledo; Yolanda Freile-Pelegrín; Mario A Peña-Hernández; Cristina Rodríguez-Padilla; Laura M Trejo-Avila
Journal:  Biomed Res Int       Date:  2016-06-22       Impact factor: 3.411

Review 6.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-12

Review 7.  Influenza antivirals currently in late-phase clinical trial.

Authors:  Paulina Koszalka; Danielle Tilmanis; Aeron C Hurt
Journal:  Influenza Other Respir Viruses       Date:  2017-02-28       Impact factor: 4.380

8.  Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.

Authors:  Rajith K R Rajoli; Henry Pertinez; Usman Arshad; Helen Box; Lee Tatham; Paul Curley; Megan Neary; Joanne Sharp; Neill J Liptrott; Anthony Valentijn; Christopher David; Steven P Rannard; Ghaith Aljayyoussi; Shaun H Pennington; Andrew Hill; Marta Boffito; Steve A Ward; Saye H Khoo; Patrick G Bray; Paul M O'Neill; W David Hong; Giancarlo A Biagini; Andrew Owen
Journal:  Br J Clin Pharmacol       Date:  2020-12-01       Impact factor: 4.335

9.  The Modulation of Cholesterol Metabolism Is Involved in the Antiviral Effect of Nitazoxanide.

Authors:  Claudio Fenizia; Salomè Valentina Ibba; Claudia Vanetti; Sergio Strizzi; Jean-François Rossignol; Mara Biasin; Daria Trabattoni; Mario Clerici
Journal:  Infect Dis Rep       Date:  2021-07-14

Review 10.  Clinical Implications of Antiviral Resistance in Influenza.

Authors:  Timothy C M Li; Martin C W Chan; Nelson Lee
Journal:  Viruses       Date:  2015-09-14       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.